Data Sharing Statement

Nollen. Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation. *JAMA Netw Open*. Published January 19, 2021. doi:10.1001/jamanetworkopen.2020.32053

**Data**

**Data available:** Yes  
**Data types:** Deidentified participant data  
**How to access data:** [https://www.pfizer.com/science/clinical-trials/trial-data-and-results](https://www.pfizer.com/science/clinical-trials/trial-data-and-results)  
**When available:** With publication

**Supporting Documents**

**Document types:** None

**Additional Information**

**Who can access the data:** Researchers whose proposed use of the data has been approved  
**Types of analyses:** For a specified purpose  
**Mechanisms of data availability:** With a signed data access agreement  
**Any additional restrictions:** Upon request, and subject to certain criteria, conditions, and exceptions (see [https://www.pfizer.com/science/clinical-trials/trial-data-and-results](https://www.pfizer.com/science/clinical-trials/trial-data-and-results) for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices: (1) for indications that have been approved in the USA and/or EU; or (2) in programs that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.